Alnylam's AMVUTTRA® Wins Canadian Reimbursement Nod for ATTR Cardiomyopathy
Event summary
- Canada's Drug Agency (CDA) issued a positive reimbursement recommendation for Alnylam's AMVUTTRA® (vutrisiran) for treating cardiomyopathy in ATTR amyloidosis patients.
- AMVUTTRA® received expanded approval from Health Canada in December 2025 for this indication, originally approved in 2023 for polyneuropathy in hATTR amyloidosis.
- The HELIOS-B Phase 3 study supported the recommendation, showing significant reductions in mortality and cardiovascular events.
- AMVUTTRA® is the first and only RNAi therapeutic targeting the root cause of ATTR amyloidosis.
The big picture
This approval solidifies Alnylam's leadership in RNAi therapeutics, addressing a critical unmet need in ATTR cardiomyopathy treatment. The positive reimbursement recommendation could set a precedent for other regulatory bodies, potentially expanding AMVUTTRA®'s global footprint. The success of the HELIOS-B study underscores the therapeutic potential of targeting the root cause of genetic diseases through RNAi.
What we're watching
- Reimbursement Timing
- Whether Canadian patients will gain swift access to AMVUTTRA® following the positive recommendation.
- Market Expansion
- How Alnylam will leverage this approval to expand AMVUTTRA®'s reach in other global markets.
- Competitive Dynamics
- Whether AMVUTTRA®'s success will pressure competitors to accelerate development of similar RNAi therapeutics.